| 1. Steinstraesser L, Hauk J, Al-Benna S, Langer S, Ring A, Kesting M, et al. Genotoxic and cytotoxic activity of host defense peptides against human soft tissue sarcoma in an in vitro model. Drug Chem Toxicol 2012;35(1):96-103. [DOI via Crossref] | | | | 2. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phospho-protein binding domain. Science 2003;302 (5645): 639-42. [DOI via Crossref] | | | | 3. Chaudhary S, Pinkston J, Rabile MM, Van Horn JD. Unusual reactivity in a commercial chromium supplement compared to baseline DNA cleavage with synthetic chromium complexes. Journal of Inorganic Biochemistry 2005;99:787-94. [DOI via Crossref] | | | | 4. Kitts CL, Green CE, Otley RA, Alvarez MA, Unkefer PJ. Type I nitroreductases in soil enterobacteria reduce TNT (2,4,6,-trinitrotoluene) and RDX (hexahydro-1,3,5-trinitro-1,3,5-triazine). Can J Microbiol. 2000;46(3):278-82. [DOI via Crossref] | | | | 5. Andra J, Jakovkin I, Grotzinger J, Hecht O, Krasnosdembskaya AD, Goldmann T, et al. Structure and mode of action of the antimicrobial peptide arenicin. Biochem J 2008;410:113-22. [DOI via Crossref] | | | | 6. Koncar H. In Vitro Genotoxicity Testing. National Institute of Biology. 2011. | | | | 7. Yamane K, Tsuruo T. Conserved BRCT regions of TopBP1 and of the tumor suppressor BRCA1 bind strand breaks and termini of DNA. Oncogene 1999;18(37):5194-203. [DOI via Crossref] | | | | 8. U.S. Department of Health and Human Services, Food and Drug Administration, CDER, CBER. Guidance for Industry - Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. 2005. Available from: URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079250.pdf | | |
|
|
